Summary
The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m2 IV infusion over 30–45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0–2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5%). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mm3). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bender RA, Hamel E, Hande KR: Plant alkaloids in cancer chemotherapy.In Chabner BA, Collins JM (eds): Cancer Chemotherapy, Principles and Practice, pp. 262–270. Philadelphia, PA, Lippincott, 1990.
Roed H, Vindelov LL, Christensen IJ, Spang-Thomsen M, Hansen HH: The effect of the two epidophyllotoxin derivative etoposide (VP-16) and Teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemother Pharmacol 99:16–20, 1990.
Clark PI, Slevin ML: The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223–252, 1987.
Kelsen DP, Magill GB, Cheng E, Dukeman M, Sordillo P, Heelan R, Yagoda A: Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 67:509–510, 1983.
Oishi N, Fleming T, Laufman L, Ungerleider JS, Natale RB, Einstein AB, Von Hoff DD, Macdonald JS: VM-26 in colorectal carcinoma: A Southwest Oncology Group study. Invest New Drugs 8:93–95, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berenberg, J.L., Tangen, C., Macdonald, J.S. et al. VM-26 in gastric cancer. Invest New Drugs 11, 333–334 (1993). https://doi.org/10.1007/BF00874433
Issue Date:
DOI: https://doi.org/10.1007/BF00874433